Publication:
Targeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues.

Simple item page
cris.virtualsource.author-orcidf618d47b-2349-48a6-a9b4-74989a01812f
dc.contributor.authorBorradori, Luca
dc.contributor.authorHertl, Michael
dc.date.accessioned2024-12-30T07:07:30Z
dc.date.available2024-12-30T07:07:30Z
dc.date.issued2024-12-06
dc.description.sponsorshipClinic of Dermatology
dc.identifier.doi10.48620/78752
dc.identifier.pmid39657119
dc.identifier.publisherDOI10.1093/bjd/ljae465
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/194739
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ispartofBritish Journal of Dermatology
dc.relation.issn1365-2133
dc.relation.issn0007-0963
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.titleTargeting type 2 inflammation in bullous pemphigoid (BP): dupilumab as game changer opens new avenues.
dc.typearticle
dspace.entity.typePublication
oairecerif.author.affiliationClinic of Dermatology
oairecerif.author.affiliation2Clinic of Dermatology
unibe.contributor.roleauthor
unibe.contributor.roleauthor
unibe.description.ispublishedinpress
unibe.refereedtrue
unibe.subtype.articlecontribution

Files

Original bundle
Now showing 1 - 1 of 1
Name:
ljae465.pdf
Size:
135.61 KB
Format:
Adobe Portable Document Format
File Type:
text
Content:
accepted
Download

Collections

Publications